Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Navarro González, Juan Francisco
• dc.contributor.author Arenas Jiménez, María Dolores
• dc.contributor.author Henríquez Palop, Fernando
• dc.contributor.author Lloret, María Jesús
• dc.contributor.author Molina, Pablo
• dc.contributor.author Ríos Moreno, Francisco
• dc.contributor.author Macia Lagier, María Asunción
• dc.contributor.author Espinel, Laura
• dc.contributor.author Sánchez, Emilio
• dc.contributor.author Lago, Mar
• dc.contributor.author Crespo, Antonio
• dc.contributor.author Bover, Jordi
• dc.date.accessioned 2021-04-22T06:55:22Z
• dc.date.available 2021-04-22T06:55:22Z
• dc.date.issued 2021
• dc.description.abstract Background: The efficacy and safety of sucroferric oxyhydroxide (SO) have been reported in clinical trials. However, real-life data are scarce. This study presents data on the use, efficacy and safety of SO in real clinical practice. Methods: We performed a retrospective multicentre study, without any influence on the prescription decisions, that included 220 patients from 11 Spanish centres. Demographic, treatment, analytical and nutritional parameters and adherence, side effects and dropout rates were collected during 6 months. Results: SO was initiated due to inadequate control of serum phosphate (P) in 70% of participants and in 24.5% to reduce the number of tablets. Monotherapy with SO increased from 44% to 74.1%, with a reduction in the average daily number of sachets/tablets from six to two. Serum P decreased by 20% (4.6 ± 1.2 versus 5.8 ± 1.3 mg/dL; P < 0.001), with a significant reduction in intact parathyroid hormone levels (P < 0.01). The percentage of patients with adequate serum P control at threshold levels of 5 and 4.5 mg/dL increased by 45.4% and 35.9%, respectively. Serum ferritin was not modified, while the transferrin saturation index increased significantly (P = 0.04). Serum albumin and normalized protein catabolic rate, when normalized by serum P, increased, averaging 37% and 39%, respectively (P < 0.001). Adherent patients increased from 28.2% to 52.7%. Adverse effects were reported by 14.1% of participants, with abandonment of treatment in 9.5%. Conclusions: The use of SO in real-life results in better control of serum P, a reduction in the number of tablets and an improvement in therapeutic adherence. In addition, it may be beneficial with regards to secondary hyperparathyroidism and nutritional status.
• dc.format.mimetype application/pdf
• dc.identifier.citation Navarro-González JF, Arenas MD, Henríquez-Palop F, Lloret MJ, Molina P, Ríos Moreno F, Macia-Lagier MA, Espinel L, Sánchez E, Lago M, Crespo A, Bover J. Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study. Clin Kidney J. 2021;14(2):681-7. DOI: 10.1093/ckj/sfaa226
• dc.identifier.doi http://dx.doi.org/10.1093/ckj/sfaa226
• dc.identifier.issn 2048-8505
• dc.identifier.uri http://hdl.handle.net/10230/47185
• dc.language.iso eng
• dc.publisher Oxford University Press
• dc.relation.ispartof Clin Kidney J. 2021;14(2):681-7
• dc.rights © The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Haemodialysis
• dc.subject.keyword Hyperphosphataemia
• dc.subject.keyword Nutritional status
• dc.subject.keyword Sucorferric oxyhydroxide
• dc.subject.keyword Therapeutic adherence
• dc.title Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion